Market Currents
The FDA OKs XenoPort's (XNPT -3.6%) and GSK's Horizant drug to treat post-herpetic neuralgia, or...
-
Thursday, June 7, 2012, 9:05 AM ETThe FDA OKs XenoPort's (XNPT -3.6%) and GSK's Horizant drug to treat post-herpetic neuralgia, or nerve pain related to shingles, which affects around 100K people a year in the U.S. GSK will pay XenoPort a $10M milestone payment following the first sales of the treatment. XenoPort is already approved for restless legs syndrome.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
